戻る Agenda
Towards an Effective Virtual R&D Team for Faster Accessing of the East Asian Market
Session Chair(s)
Deborah Chee, MD, PHD, MBA
Chief Executive Officer
Connect Clinical Sciences, Korea, Republic of
Strategic use of a “virtual” R&D team model could benefit companies that have limited capabilities in East Asian markets - including Japan, China, Korea and Taiwan - to minimize the drug lag and to maximize product value in these markets.
Learning Objective : Describe the benefits of the virtual R&D team model for companies with limited R&D capabilities in certain target markets; Recognize the virtual R&D team model as a promising option for accessing the East Asian market.
Speaker(s)
Challenges and Successes of Virtual R&D Teams for East Asia
Chris Bruenger, MD
IDEC Inc., Japan
President and CEO
Drug Lag, Regulatory Innovation and the Role of the Academic Center in East Asia
Howard Lee
Seoul National University Hospital and College of Medicine, Korea, Republic of
Professor, Department of Clinical Pharmacology and Therapeutics
Program Management: Striving for Productive Conversations, Team Chemistry and a Drive for Results
Philip Bonasia, PHD
Sunovion Pharmaceuticals Inc., United States
Head of Regen Med & Pharma Innovation